MARKET

PLSE

PLSE

Pulse
NASDAQ

Real-time Quotes | Nasdaq Last Sale

21.53
-1.33
-5.80%
Opening 10:34 09/20 EDT
OPEN
21.98
PREV CLOSE
22.86
HIGH
22.27
LOW
20.51
VOLUME
10.85K
TURNOVER
--
52 WEEK HIGH
45.82
52 WEEK LOW
10.56
MARKET CAP
637.52M
P/E (TTM)
-9.1753
1D
5D
1M
3M
1Y
5Y
BRIEF-Pulse Biosciences Selling Securityholder May Offer Or Sell 3 Million Shares
reuters.com · 09/03 21:31
Pulse Biosciences to Participate in the H.C. Wainwright Global Investment Conference
HAYWARD, Calif., September 02, 2021--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company introducing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced plans to participate in the upcoming virt...
Business Wire · 09/02 20:05
Is Pulse Biosciences (NASDAQ:PLSE) Weighed On By Its Debt Load?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Simply Wall St. · 09/02 16:43
Pulse Biosciences Announces Appointment of Mitchell E. Levinson as Chief Strategy Officer
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX(R) System powered by Nano-Pulse Stimulation(TM) (NPS(TM)) technology, today announced the appointment of Mitchell E. Levinson to the newly created role ...
Business Wire · 08/19 20:05
Pulse Biosciences Appoints Mitchell Levinson Chief Strategy Officer
MT Newswires · 08/19 16:41
Pulse Biosciences Q2 EPS $(0.58) Beats $(0.75) Estimate
Pulse Biosciences (NASDAQ:PLSE) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.75) by 22.67 percent. This is a 9.43 percent decrease over losses of $(0.53) per share from
Benzinga · 08/09 21:23
BRIEF-Pulse Biosciences Posts Quarterly Loss Per Share Of $0.58
reuters.com · 08/09 20:52
-- Earnings Flash (PLSE) PULSE BIOSCIENCES Reports Q2 Loss $-0.58, vs. Street Est of $-0.52
MT Newswires · 08/09 16:21
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PLSE. Analyze the recent business situations of Pulse through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PLSE stock price target is 38.00 with a high estimate of 46.00 and a low estimate of 28.00.
EPS
Institutional Holdings
Institutions: 69
Institutional Holdings: 3.22M
% Owned: 10.89%
Shares Outstanding: 29.61M
TypeInstitutionsShares
Increased
12
196.44K
New
6
113.36K
Decreased
20
193.26K
Sold Out
10
211.85K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-0.42%
Healthcare Equipment & Supplies
-0.73%
Key Executives
Non-Executive Chairman/Independent Director
Robert Duggan
President/Chief Executive Officer/Director
Darrin Uecker
Chief Financial Officer/Executive Vice President - Finance/Treasurer/Secretary
Sandra Gardiner
Executive Vice President/General Manager
Edward Ebbers
Director
Mitchell Levinson
Independent Director
Kenneth Clark
Independent Director
Manmeet Soni
Independent Director
Richard van den Broek
Independent Director
Mahkam Zanganeh
No Data
About PLSE
Pulse Biosciences, Inc. is a clinical-stage medical device company using a platform technology called Nano-Pulse stimulating (NPS). NPS is a non-thermal, precise, focal drug-free electroceutical treatment technology that initiates cell death within treated tissue. NPS provides treatment in a range of immuno-oncology, dermatology and aesthetic applications. It offers treatment for minimally invasive applications, such as cardiac ablation, lung disease, Barret's esophagus, thyroid nodules, and ear, nose and throat (ENT) papillomas. The Company is developing PulseTx system (PulseTx), a system for the delivery of NPS treatments. The PulseTx system delivers NPS pulses through its tunable pulse generator and its planned suite of electrodes. The PulseTx system pulses are applied directly to tissue through electrodes, creating transient nanometer pores in cell and organelle membranes.

Webull offers kinds of Pulse Biosciences Inc stock information, including NASDAQ:PLSE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PLSE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PLSE stock methods without spending real money on the virtual paper trading platform.